Literature DB >> 23380979

[The influence of visual rehabilitation on secondary depressive disorders due to age-related macular degeneration. A randomized controlled pilot study].

A Mielke1, K Wirkus, R Niebler, G Eschweiler, N X Nguyen, S Trauzettel-Klosinski.   

Abstract

BACKGROUND: Age-related macular degeneration (AMD) often leads to visual impairment, loss of reading ability, reduced quality of life and secondary depression. The present study examined if visual rehabilitation has a preventive effect on secondary depression in these patients.
MATERIAL AND METHODS: In a controlled pilot study 20 patients were randomized into 2 groups whereby 9 underwent visual rehabilitation at first examination and 11 received magnifying visual aids only after 3 months. Psychosocial status was assessed by the geriatric depression scale (GDS) and the German version of the Centre for Epidemiologic Studies depression (CES-D) scale (main outcome parameter), cognitive status by the dementia detection test (DemTecT), minimental status (MMS) and quality of life by the National Eye Institute visual function questionnaire (NEI-VFQ 25). Ophthalmological examination included reading speed measurement by standardized texts (International Reading Speed Texts; IReST).
RESULTS: Parameters of the CES-D scale, DemTect and the subitem exercise of social roles of the NEI-VFQ 25 emerged in a divergent manner. Patients of the rehabilitation group became less depressive and improved in cognitive and social abilities and in the control group vice versa. The interactive effect of group and time was statistically significant for all three tests.
CONCLUSIONS: Visual rehabilitation has a positive impact on depression as well as cognitive status and quality of life in patients with AMD. The effects have to be confirmed in future studies with more patients and a longer observation period.

Entities:  

Mesh:

Year:  2013        PMID: 23380979     DOI: 10.1007/s00347-012-2715-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  26 in total

Review 1.  Age-related macular degeneration and depression: a review of recent research.

Authors:  Robin J Casten; Barry W Rovner; William Tasman
Journal:  Curr Opin Ophthalmol       Date:  2004-06       Impact factor: 3.761

2.  Development of the 25-item National Eye Institute Visual Function Questionnaire.

Authors:  C M Mangione; P P Lee; P R Gutierrez; K Spritzer; S Berry; R D Hays
Journal:  Arch Ophthalmol       Date:  2001-07

3.  New standardised texts for assessing reading performance in four European languages.

Authors:  G A Hahn; D Penka; C Gehrlich; A Messias; M Weismann; L Hyvärinen; M Leinonen; M Feely; G Rubin; C Dauxerre; F Vital-Durand; S Featherston; K Dietz; S Trauzettel-Klosinski
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

4.  [Quality of life by limited vision in old age: the example of age-related macula degeneration].

Authors:  H-W Wahl; V Heyl; N Langer
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

5.  Dissatisfaction with performance of valued activities predicts depression in age-related macular degeneration.

Authors:  Barry W Rovner; Robin J Casten; Mark T Hegel; Walter W Hauck; William S Tasman
Journal:  Int J Geriatr Psychiatry       Date:  2007-08       Impact factor: 3.485

6.  Age-related macular degeneration: self-management and reduction of depressive symptoms in a randomized, controlled study.

Authors:  Barbara L Brody; Anne-Catherine Roch-Levecq; Robert M Kaplan; Christine Y Moutier; Stuart I Brown
Journal:  J Am Geriatr Soc       Date:  2006-10       Impact factor: 5.562

7.  Quality of life of low-vision patients and the impact of low-vision services.

Authors:  I U Scott; W E Smiddy; J Schiffman; W J Feuer; C J Pappas
Journal:  Am J Ophthalmol       Date:  1999-07       Impact factor: 5.258

8.  Improvement of reading speed after providing of low vision aids in patients with age-related macular degeneration.

Authors:  Nhung Xuan Nguyen; Malte Weismann; Susanne Trauzettel-Klosinski
Journal:  Acta Ophthalmol       Date:  2009-11       Impact factor: 3.761

9.  The influence of reduced visual acuity on age-related decline in spatial working memory: an investigation.

Authors:  Zaira Cattaneo; Ela Bhatt; Lotfi B Merabet; Alfredo Pece; Tomaso Vecchi
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2008-05-22

10.  Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.

Authors:  Andrew Lotery; Xiao Xu; Gergana Zlatava; Jane Loftus
Journal:  Br J Ophthalmol       Date:  2007-05-15       Impact factor: 4.638

View more
  5 in total

1.  [Requirements for low vision magnification aids in age-related macular degeneration: Data from the Tübingen low vision clinic (comparison of 2007-2011 with 1999-2005)].

Authors:  E K Altpeter; N X Nguyen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

2.  [Current possibilities of visual rehabilitation].

Authors:  S Trauzettel-Klosinski
Journal:  Ophthalmologe       Date:  2018-10       Impact factor: 1.059

3.  Low vision rehabilitation in improving the quality of life for patients with impaired vision: A systematic review and meta-analysis of 52 randomized clinical trials.

Authors:  Jianhua Liu; Jige Dong; Yaping Chen; Weidong Zhang; Shuai Tong; Jiangzhou Guo
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

4.  Low vision rehabilitation for better quality of life in visually impaired adults.

Authors:  Ruth Ma van Nispen; Gianni Virgili; Mirke Hoeben; Maaike Langelaan; Jeroen Klevering; Jan Ee Keunen; Ger Hmb van Rens
Journal:  Cochrane Database Syst Rev       Date:  2020-01-27

5.  Remaining visual field and preserved subjective visual functioning prevent mental distress in patients with visual field defects.

Authors:  Carolin Gall; Doreen Brösel; Bernhard A Sabel
Journal:  Front Hum Neurosci       Date:  2013-09-18       Impact factor: 3.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.